Avantor Completes Multi-Year Expansion To Expand Global Hydration Capabilities

Avantor has completed a multi-year expansion at its flagship European GMP manufacturing site in Gliwice, Poland, to increase its global hydration capabilities. Ger Brophy, Ph.D., Chair, Scientific Advisory Board, Avantor, outlined the investment at the DCAT Member Company Announcement Forum at DCAT Week.
The new production facility’s advanced technologies quadruple the site’s capacity to formulate and fill hydrated solutions with USP purified water and water-for-injection (WFI) quality water. These high-purity solutions are used in buffer preparations, cell-culture media, clean-in-process, and formulation processes.
The Gliwice expansion is part of Avantor’s broader effort to enhance its global production network. In recent years, the company has increased manufacturing capacity and introduced new products to support bioprocessing. The Poland project builds on a recent expansion at the company’s Aurora, Ohio, manufacturing site, which tripled hydration solutions production to support the North American market. Additionally, a new production facility at its Phillipsburg, New Jersey, site has doubled the output of synthesized salts, a key component in solutions manufacturing.
Adding to the company’s existing WFI-quality water buffer manufacturing capabilities in place, the facility investments in Gliwice and Aurora increase Avantor’s capacity to support biomanufacturing globally. The Gliwice site was designed with built-in flexibility to expand capacity as the business grows in years to come.
In addition to increasing manufacturing capacity, Avantor has also expanded its research and innovation capabilities. In November 2024, the company opened its 60,000-square-foot Bridgewater Innovation Center in New Jersey. This facility doubles Avantor’s previous lab and pilot-plant capacity and is designed to support upstream and downstream process development, analytical testing, and viral vector research.
Overall, Avantor operates in more than 30 countries, with a global network that includes 12 cGMP facilities, 14 innovation centers, and over 200 manufacturing, distribution, and sales sites.